Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $81.3 million.

  • Nurix Therapeutics' Non-Current Assets rose 6277.52% to $81.3 million in Q4 2025 from the same period last year, while for Nov 2025 it was $290.8 million, marking a year-over-year increase of 2639.55%. This contributed to the annual value of $81.3 million for FY2025, which is 6277.52% up from last year.
  • Nurix Therapeutics' Non-Current Assets amounted to $81.3 million in Q4 2025, which was up 6277.52% from $81.9 million recorded in Q3 2025.
  • Over the past 5 years, Nurix Therapeutics' Non-Current Assets peaked at $165.7 million during Q4 2021, and registered a low of $40.2 million during Q3 2023.
  • In the last 5 years, Nurix Therapeutics' Non-Current Assets had a median value of $81.6 million in 2023 and averaged $85.9 million.
  • As far as peak fluctuations go, Nurix Therapeutics' Non-Current Assets surged by 18173.9% in 2021, and later plummeted by 6147.49% in 2023.
  • Nurix Therapeutics' Non-Current Assets (Quarter) stood at $165.7 million in 2021, then plummeted by 40.65% to $98.3 million in 2022, then plummeted by 38.87% to $60.1 million in 2023, then dropped by 16.87% to $50.0 million in 2024, then skyrocketed by 62.78% to $81.3 million in 2025.
  • Its last three reported values are $81.3 million in Q4 2025, $81.9 million for Q3 2025, and $76.2 million during Q2 2025.